Tempus AI has entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data, software, and AI models for therapeutic development. The agreements, which cover both oncology and neurology data, are expected to generate aggregate cash payments of $192.5 million to Tempus over approximately five years.
Key Details
- Total Value: The agreements provide for $192.5 million in aggregate cash payments to Tempus, consisting of $137.5 million from BMS and $55 million from Pathos over a five-year period.
- Oncology Agreement with BMS: A $137.5 million Statement of Work grants BMS access to Tempus's de-identified oncology data and its Lens software platform for analysis. The term of this agreement extends to December 31, 2031.
- Neurology Agreement with Pathos: Tempus will license 500,000 de-identified neurology patient records and an agentic analysis tool to Pathos for up to $55 million. Pathos will sublicense this data and tool to BMS to support therapeutic development.
- Related Party Transaction: The agreements with Pathos AI were classified as a related-person transaction and were reviewed and approved by a special committee of disinterested directors on Tempus's board.